Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPT3
- Development stage
- Preclinical
- Lead developer
- Remedy Plan Therapeutics
- Modality
- Small Molecules
01
Overview
RPT3 is a preclinical-stage small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) developed by Remedy Plan Therapeutics for the treatment of obesity. The drug utilizes a proprietary approach of 'tunable' or fractional NAMPT inhibition, designed to modulate cellular energy metabolism and NAD+ levels while avoiding the systemic toxicities associated with complete NAMPT blockade. By targeting the rate-limiting enzyme of the NAD+ salvage pathway, RPT3 aims to address metabolic dysfunction underlying obesity. The program is currently in the lead optimization phase of development.
- Other names
- Remedy Plan Australia-NAMPT-small molecule-obesity
02
Targets
NAMPT
Beyond the preview
Go deeper on RPT3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RPT3.